Last reviewed · How we verify

Spiriva HandiHaler — Competitive Intelligence Brief

Spiriva HandiHaler (Spiriva HandiHaler) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory.

marketed Long-acting muscarinic antagonist (LAMA) M3 muscarinic acetylcholine receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Spiriva HandiHaler (Spiriva HandiHaler) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Spiriva HandiHaler delivers tiotropium, a long-acting anticholinergic agent that blocks muscarinic receptors in airway smooth muscle to cause bronchodilation and improve airflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Spiriva HandiHaler TARGET Spiriva HandiHaler Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketed Long-acting muscarinic antagonist (LAMA) M3 muscarinic acetylcholine receptor
Detrol LA Detrol LA Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed Muscarinic receptor antagonist M2 and M3 muscarinic acetylcholine receptors
salbutamol + ipratropium bromide nebules salbutamol + ipratropium bromide nebules Imperial College London marketed Combination bronchodilator (beta-2 agonist + anticholinergic) Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)
Indacaterol/glycopyrronium Indacaterol/glycopyrronium Orion Corporation, Orion Pharma marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
Drug: ipratropium (AtroventTM) Drug: ipratropium (AtroventTM) AstraZeneca marketed Anticholinergic bronchodilator M3 muscarinic acetylcholine receptor
Solifenacin succinate treatment Solifenacin succinate treatment Barrie Urology Associates marketed Muscarinic M3 receptor antagonist M3 muscarinic acetylcholine receptor
Oxybutynin chloride, extended-release Oxybutynin chloride, extended-release US Department of Veterans Affairs marketed Anticholinergic agent M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

  1. GlaxoSmithKline · 9 drugs in this class
  2. AstraZeneca · 3 drugs in this class
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
  4. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  6. Lupin, Inc. · 1 drug in this class
  7. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Spiriva HandiHaler — Competitive Intelligence Brief. https://druglandscape.com/ci/spiriva-handihaler. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: